Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s progress was lauded by Peel Hunt in research that followed the speciality pharma group's interims on Wednesday.
"We continue to think the current underlying combination in pricing and prescription growth is encouraging," the City broker said in a note to clients.
Total prescriptions for its anaemia treatment ACCRUFeR were 65,200 at a quarterly growth rate of 25%. Peel pointed out that Shield is currently valued at 0.66 times 2025's forecast sales and 1.8 times this year's, "despite having an approved drug on the market and selling".
In early afternoon trading, the stock was 8% at 4.85p.